Etoposide Can be Safely Eliminated in Pediatric Acute Myeloid Leukemia
- Dec 17, 2025
- 1 min read
Removing etoposide from frontline induction chemotherapy did not appear to negatively affect key outcomes for patients with pediatric acute myeloid leukemia (AML), according to recent findings from a Children’s Oncology Group (COG) clinical trial presented at the ASH Annual Meeting 2025.
I truly appreciate this article because it explains valuable ideas clearly, encourages reflection, and provides helpful insights that readers from diverse backgrounds can easily understand.
https://medium.com/@imunkita